recently developed a CD276-directed antibody-drug conjugate (ADC) that exhibited anti-tumor activity in non-small cell lung cancer (NSCLC) models, primarily by delivering a cytotoxic MMAF payload (42). Here, CD276 is linked to non-small cell lung carcinoma.